Spirodiketopiperazine-based CCR5 antagonists, showing improved pharmacokinetic profiles without reduction in antagonist activity, were designed and synthesized. We also demonstrate the anti-HIV activity of a representative compound 12, as measured in a p24 assay.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7553643 | PMC |
http://dx.doi.org/10.1016/j.bmcl.2009.11.018 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!